Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban added to antiplatelet therapy after recent acute coronary syndrome
jRCT2080220695Phase 3
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Rivaroxaban + antiplatelet therapy with Placebo + antiplatelet therapy (2 arms). Primary endpoints: Composite primary efficacy endpoint and Primary safety endpoint.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on jRCT2080220695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220695.